Prevalence of Fibromyalgia in France: a multi-step study research combining national screening and clinical confirmation: The DEFI study (Determination of Epidemiology of FIbromyalgia). by Perrot, Serge et al.
Prevalence of Fibromyalgia in France: a multi-step study
research combining national screening and clinical
confirmation: The DEFI study (Determination of
Epidemiology of FIbromyalgia).
Serge Perrot, Eric Vicaut, Dominique Servant, Philippe Ravaud
To cite this version:
Serge Perrot, Eric Vicaut, Dominique Servant, Philippe Ravaud. Prevalence of Fibromyalgia
in France: a multi-step study research combining national screening and clinical confirmation:
The DEFI study (Determination of Epidemiology of FIbromyalgia).. BMC Musculoskeletal
Disorders, BioMed Central, 2011, 12 (1), pp.224. <10.1186/1471-2474-12-224>. <inserm-
00633577>
HAL Id: inserm-00633577
http://www.hal.inserm.fr/inserm-00633577
Submitted on 18 Oct 2011
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destine´e au de´poˆt et a` la diffusion de documents
scientifiques de niveau recherche, publie´s ou non,
e´manant des e´tablissements d’enseignement et de
recherche franc¸ais ou e´trangers, des laboratoires
publics ou prive´s.
RESEARCH ARTICLE Open Access
Prevalence of fibromyalgia in France: a multi-step
study research combining national screening and
clinical confirmation: The DEFI study
(Determination of Epidemiology of FIbromyalgia)
Serge Perrot1*, Eric Vicaut2, Dominique Servant3 and Philippe Ravaud4
Abstract
Background: Fibromyalgia is a common disease, but little is known on its real prevalence in France. This
epidemiological study aimed to assess fibromyalgia (FM) prevalence in the French metropolitan population, based
on a multi-step sampling analysis, combining national screening and clinical confirmation by trained specialists.
Methods: a sampling method on the entire national territory was used: patients over 18 years of age accepting to
take part in the study were contacted by telephone using the LFES Questionnaire, a screening test for FM. The, for
patients detected by the LFESQ, a visit with a FM-trained rheumatologist was proposed to confirm FM, based on
1990 ACR criteria. Each detected patient completed the following self-questionnaires: SF36, HADS, stress VAS, Co-
morbidities and Regional pain score.
Results: 3081 patients were contacted in 5 representative French regions, of which 232 patients were screened for
FM. A fibromyalgia diagnosis was then confirmed by rheumatologist in 20 cases (17 female and 3 male, 56.9 ± 13.2
years). The final estimated FM prevalence was 1.6 (CI95: 1.2%; 2.0%). No significant difference was detected
between the patients accepting (CS+) and refusing (CS-) rheumatologist visit for the SF36 score, regional pain
score, stress VAS scale and co-morbidities. In patients detected for FM by the LFESQ, we found a statistically
significant decrease in quality of life and a statistically significant increase in stress level in patients with a
confirmed diagnosis (FM+) (6.3 ± 1.9) compared to patients with an invalidated diagnosis (FM-) (4.4 ± 2.8; p =
0.007). The study also demonstrated a significant association, independently of ACR criteria, between the diagnosis
of FM and several factors such as regional pain score > 10, elevated stress level, low SF36 scale score and presence
of gastro-intestinal disorder co-morbidities.
Conclusion: Fibromyalgia is a common condition; the 1.6% prevalence calculated in the French population in our
study corroborates the figures published in the European literature. Our results also suggest that criteria such as
regional pain score, stress level or SF36 quality of life, could represent useful tools in fibromyalgia diagnosis.
Background
Fibromyalgia (FM) is a debilitating chronic disease char-
acterized by pain described by patients as muscular and/
or skeletal, diffuse and chronic, exacerbated by pressure
from some tendon insertion points associated with
severe long-term fatigue. For many years, FM diagnosis
was based on the 1990 American College of Rheumatol-
ogy (ACR) classification criteria [1], initially not dedi-
cated to the diagnosis. New diagnosis criteria [2] and
screening tool [3] have been proposed in 2010. Progress
in imaging (MRI and PET) [4] and neurobiology in the
last 10 years [5] have enabled a better understanding of
the physiopathology of this disease which appears in
association with a central pain modulation disorder
characterized by nociceptive and neuropathic pain path-
way dysfunction. Affected patients display a lowering of
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the pain perception threshold, with the induction of
pain by stimuli not normally inducing pain (allodynia).
Guidelines for FM management have been published by
the European League Against Fibromyalgia (EULAR) [6].
In epidemiological terms, FM is not a rare disease and
its estimated frequency varies according to the popula-
tion and the methodology. Its prevalence is reported to
be 2 to 6% in the case of patients attending general
practitioners, 5 to 8% in hospitalized patients and 14 to
20% in rheumatology consultations [7-9]. In France,
very few studies have been conducted [10] and accurate
prevalence figures for FM are not available, prevalence
figures between 0.5% and 5% have been suggested. The
aim of this study was to assess the prevalence of fibro-
myalgia in the general population in France, with a
multi-step study, combining large national screening
process and confirmed diagnosis by trained specialists.
Methods
The study in question was a multi-centre, national, cross
sectional interventional study.
General study design
A probabilistic sample of 6000 households, selected at
random from the telephone directory, was prepared in
the general population in 5 geographic representative
regions in France: the conurbations of Lille, Grenoble,
Toulouse and the Val de Marne and Ille-et-Vilaine
départements. Each region was represented by 1200
households defined as “regular households” (primary
residence and at least one member aged 18 years or
over). Ethical approval was obtained from the Ethical
Committee Paris Ile de France, and from the CNIL for
data analyses.
Selection of patients with potential or established
fibromyalgia
A single member of each household was contacted by
the IPSOS, a market-research company specialized in
poll studies, by telephone on the basis of the following
criteria: subject aged 18 years of over, accepting to take
part in the study and capable of understanding and
answering the questions. A questionnaire was completed
with the following data: total number of adult members
of the household, specifying the number of females and
males, demographic characteristics of the interviewee
(gender, month and year of birth, socio-professional
group). To determine whether the subject had fibro-
myalgia or not, the “London Fibromyalgia Epidemiology
Study Screening Questionnaire” or LFES-SQ [11], vali-
dated in its French version (10), was used for the tele-
phone interviews. A subject was deemed to have
potential or established fibromyalgia if they gave a posi-
tive response to the 4 pain criteria alone (In the past 3
months: 1. Have you had pain in muscles, bones, or
joints, lasting at least 1 week? 2. Have you had pain in
your shoulders, arms, or hands? On which side? Right,
left, or both? 3. Have you had pain in your legs or feet?
On which side? Right, left, or both? 4. Have you had
pain in your neck, chest, or back?) or to the 4 pain cri-
teria plus the 2 criteria relating to fatigue (1. Over the
past 3 months, do you often felt tired or fatigued? 2.
Does tiredness or fatigue significantly limit your
activities?)
Follow-up of patients with potential or established
fibromyalgia
In total, 24 rheumatologists (4 to 5 per region) were
selected to take part in the study. To ensure a homoge-
neous diagnosis, the rheumatologists received an exten-
sive and standardized training on chronic pain,
fibromyalgia diagnosis, and the handling of the various
questionnaires. Patients with potential or established
fibromyalgia selected following the LFES-SQ question-
naire were offered a visit with a rheumatologist to con-
firm the fibromyalgia diagnosis. Patients who refused
this consultation had the option of receiving, by mail,
questionnaires to assess the condition, the regional pain
score and questionnaires to assess some impact of the
condition: quality of life (QoL) questionnaire by SF36, as
a generic QoL questionnaire [12], emotional impact
scale by HADs (Hospital Axiety and Depression scale)
to detect anxiety and depression [13], current stress
level measured using the a 100 mm Visual Analog Scale
(VAS), presence of Co-morbidities and regional pain
score. They were asked to send back the questionnaires
via postal mail.
Diagnosis and care provided by rheumatologist
During the consultation, the rheumatologist drew up an
inventory of the patient’s profile, his/her rheumatology
or other medical history, demographic characteristics
and socio-professional status. Screening for pain sites
was performed according to the 1990 ACR criteria (1)
for FM diagnosis. A questionnaire was completed by the
rheumatologist with the following information: patient’s
demographic data, history of chronic pain, previous FM
history, patient’s previous rheumatological history,
patient’s other major medical history, ACR1990 FM cri-
teria. The patient also completed the following question-
naires, with assistance from the rheumatologist: SF36,
HADS, stress level assessed using the VAS scale, co-
morbidities and regional pain score.
Calculation of prevalence and statistical analysis
An estimation of the FM prevalence in the interviewed
population was calculated with its 95% confidence inter-
val using the formula below where Ndiagnosis is the
number of FM cases confirmed by the rheumatologist
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and Nrefusing-consultation the number of cases of FM
estimated in the population of patients refusing the con-
sultation.
Prevalence (% ) =
Ndiagnosis +
(
Ndiagnosis
Naccepting consultation
× Nrefusing consultation
)
Ninterview
× 100
The statistical analysis was conducted in SAS version
9.1.3 in Windows XP. Descriptive statistical analyses
were conducted for the quantitative variables: mean,
standard deviation, median, minimum and maximum
and 95% confidence interval (95% CI) and for the quali-
tative variables (frequencies, percentages and 95% confi-
dence interval).
Results
Between April 21, 2008 and September 29, 2008, 6000
households were contacted by telephone, 3326 subjects
accepted to take part in the study and were contacted,
of whom, 245 refused or withdrew during the question-
naire. In the end, 3081 subjects responded fully to the
telephone questionnaire (LFES-SQ). Following this selec-
tion, 232 (7.5%) subjects were classified as having poten-
tial or established fibromyalgia (LFES-SQ+). Of the 232
LFES-SQ+ patients, 96 (41.4%) attended a rheumatology
consultation (CS+), 49 (n = 21.1%) returned the patient
questionnaires without attending the consultation (CS-)
and 87 (37.5%) did not attend the consultation or com-
plete the questionnaires. The patient distribution in the
study is described in Figure 1.
Confirmation of fibromyalgia diagnosis
Of the 96 CS+ patients, a fibromyalgia diagnosis was
confirmed clinically by the rheumatologist in 20 patients
(FM+) based on ACR criteria (presence of the three fol-
lowing criteria: history of diffuse pain, chronic pain pro-
gressing for more than 3 months and pain on digital
palpation of 11 to 18 points) and invalidated in 76
patients (FM-). The latter did not meet all the ACR cri-
teria. We did not found any patient with a previous
diagnosis of FM.
Prevalence of fibromyalgia in the study population
Of the 232 patients detected with potential or estab-
lished fibromyalgia, 20 cases were confirmed by the
rheumatologist. Considering that the prevalence of FM
was identical in both groups of patients accepting and
rejecting consultation, the estimated number of cases of
FM in the CS- patients would be 28 cases, as indicated
in Table 1, bringing the total estimated number of cases
of FM in the interviewed population to 48. The esti-
mated prevalence of FM in the interviewed population
is thus 1.6% (95%CI:1.2%; 2.0%). This prevalence varied
according to the regions; 0.8% (0.1%; 1.5%) in Toulouse,
0.8% (0.2%; 1.5%) in Grenoble, 1.7% (0.7%; 2.7%) in Lille,
1.9% (0.9%; 2.9%) in Ille-et-Vilaine and 2.7% (1.3%; 4.1%)
in Val-de-Marne.
Characteristics of the study population
Table 2 describes the demographic characteristics of the
main populations analyzed. The interviewed population
(n = 3081) consisted of 61% women. Taking the patients
responding to the LFES-SQ questionnaire into account,
the LFSE-SQ+ patient group consisted of a majority of
women (71.1% vs 60.3% p = 0.001) and older subjects
compared to the LFESSQ- patient group (61.8 ± 17.3
years vs 54.4 ± 19.2 years, p < 0.0001). The patient
population accepting the consultation (CS+) consisted
of a majority of women (69.8%), the mean age was 58.4
± 14.6 years and 55.9% of those stated they had an
occupation. The time elapsed since the first chronic
pain in CS+ patients was, on average, 12.7 ± 11.6 years.
No significant difference was observed for the demo-
graphic data between the FM+ and FM- patients. Table
2 describes the co-morbidities in CS+ and CS- patient
and also in FM+ and FM- patients. No significant differ-
ence was observed with the exception of the more fre-
quent previous history of rheumatoid arthritis in the
CS- group (19.2% vs 7.4% p = 0.037) and statistically
more frequent cramp-type digestive disorders in the FM
+ patients compared to the FM- patients (79.0%; 95%CI:
60.6; 97.3) vs (48.0%; 95%CI: 36.5; 59.4, p = 0.016).
Analysis of patient questionnaires (SF36, regional pain
score and stress level assessed with VAS, anxiety and
depression)
The scores of each of the eight SF-36 scales, and the
psychological and physical summary scores were stan-
dardized to obtain a score of 0 to 100 where 50 (±10)
corresponds to the 1998 reference U.S. population [14].
The results of the harmonized SF36 scores, co-morbid-
ities, the regional pain score and the stress level VAS
scale were compared between the CS+ (n = 96) and CS-
(n = 49) with potential or established fibromyalgia and
also the FM+ (n = 20) and FM- (n = 76) patients.
For the group of patients with potential or established
fibromyalgia (n = 232), the results did not demonstrate
any significant difference for the SF36 score, RPS and
stress VAS scale. On the other hand, a statistically sig-
nificant decrease in the quality of life of the FM+ patient
group was observed compared to the FM- patient group
on 7 of the 8 scores in the SF36 scale (Figure 2). The
mean stress level measured using a visual analog scale
was statistically higher in the FM+ patients compared to
the FM- patients (6.3 ± 1.9: 95%:5.4; 7.1) vs (4.4 ± 2.8
:95%CI: 3.8; 5.1, p = 0.007). Patients were considered as
having an anxious disorder or a depressive disorder if
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the HADs subscore was higher than 10, and these are
the patients mentionned in the table 3.
The maximum values of the Regional Pain Score ran-
ged from 3.0 to 19.0 and a statistically significant differ-
ence was also observed between the FM+ and FM-
patient groups, with respect to the mean regional pain
score (13.2 ± 4.3 vs 9.0 ± 4.4, p < 0.001), as indicated in
Table 3.
Factors associated with confirmation of diagnosis by the
rheumatologist
A search for factors associated with an increase in the
likelihood of diagnosis of FM by the rheumatologist was
conducted in the patient population attending the con-
sultation (N = 96). The following factors were included
in the univariate analysis; gender, SF36, stress level VAS,
co-morbidities (long-term fatigue, cramp type digestive
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Subject without potential fibro-
myalgia N=2849 (92.5%)   
Patient attending consultation with s 
Rheumatologist    N=96 (41.4%)   
(CS+)   
Subjects refusing consultation   
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 N=87 (37.5%)   
Subjects completing patient questionnaire s   
N=49 (21.1%)  (CS - )   
  
  
  
  
  
  
  
Patient with confirmed diagnosis s   
N=20 (2 0.8%) (FM+)   
Patient with invalidated diagnosis s    
N=76 (79.2%)  (FM - )   
Population responding to 
LFES - SQ questionnaire N=3081   
Subjects with potential or
established fibromyalgia   
N=232 (7.5 %)   
General population (Subject accepting or refusing interview, for 
whom at least one data item is available)   
N=3 326    
Figure 1 Patient distribution in the study.
Table 1 Number of confirmed and estimated cases of fibromyalgia in interviewed population
A B C D E (B-C)x D/C F (D+E)
Interviewed
patients
Patients with potential or
established fibromyalgia
Patients
accepting
consultation
Number of cases of FM
confirmed by rheumatologist
Number of estimated cases of FM in
patients refusing consultation
Total number
of cases of FM
(LFES-SQ+) (CS+) (FM+) (CS-)
3081 232 96 20 28 48
LFES-SQ: London Fibromyalgia Epidemiology Study- Screening Questionnaire, FM: Fibromylagia, CS: Consultation?
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disorders, headaches, anxiety, rheumatoid arthritis, sys-
temic lupus erythematosus), and the regional pain score.
The results are summarized in figure 3 and demonstrate
that the likelihood of having an increase in the diagnosis
of fibromyalgia by the rheumatologist was statistically
linked with increases in the stress level assessed on the
VAS (p = 0.010), the presence of cramp type digestive dis-
orders (p = 0.021), a decrease in some quality of life scores
such as the physical health (p = 0.009) and mental health
(MCS) (p = 0.012) scale and an increase in the regional
pain score (p < 0.001). A correlation study between the
regional pain score and the confirmation of diagnosis by
the rheumatologist was conducted and demonstrated that
the best sensitivity/specificity ratio was obtained for a
regional pain score threshold equal to 10 with a 75% sensi-
tivity and a 67.1% specificity (Table 4).
Limitations of the study
Our study has some limitations, related to the methodology:
patients were contacted by telephone, and the LFESQ was
used by telephone interviews to screen the patients. Patients
that did not accept to attend a visit to a rheumatolgist were
asked to fill-in questionnaires, and to send it back by postal
mail. All these steps were performed without physician.
Discussion
To assess the FM prevalence in the French population,
this epidemiological study was conducted based on the
Table 2 Demographic characteristics of populations analyzed
Patients responding to LFES-SQ
questionnaire
Patients with potential or
established fibromyalgia
Patients attending consultation with
rheumatologist
LFES-SQ+* LFES-SQ- CS+ CS- FM + FM -
Number of patients 232 2849 96 49 20 76
Age; Mean ± SD 95%
CI
61.8 ± 17.3
[59.5;64.0]
54.4 ± 19.2
[53.7;55.1]
58.2 ± 14.7
[55.2;61.2]
62.1 ± 18.6
[56.7;67.4]
56.9 ± 13.2
[50.7;63.1]
58.8 ± 15.0
[55.4;62.3]
Males N (%) 95%CI 67 (28. 9)
[23.1;34.71]
1132 (39.7) [37.9;41.5] 28 (29.2)
[20.1;38.3]
16 (32.7)
[19.5;45.8]
3 (15.0) [0.0;30.7] 26 (34.2)
[23.5;44.9]
Females N (%) 95%CI 165 (71.1)
[65.3;77.0]
1717 (60.3)
[58.5;62.1]
68 (70.8)
[61.7;79.9]
33 (67.4)
[54.2;80.5]
17 (85.0)
[69.4;100.0]
50 (65.8)
[55.1;76.5]
LFES-SQ = London Fibromyalgia Epidemiology Study- Screening Questionnaire; CS+: patients attending consultation with rheumatologist and completing
questionnaire; CS-: patients completing questionnaire but not attending consultation with rheumatologist; FM+: = confirmed diagnosis of fibromyalgia; FM-: =
non-confirmed diagnosis of fibromyalgia
FM+: = confirmed diagnosis of fibromyalgia; FM-: = non-confirmed diagnosis of fibromyalgia 
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p=0,006 p<0,0001 
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Figure 2 Comparison of mean SF36 scores between patients with confirmed (FM+) and non-confirmed (FM-) fibromyalgia diagnosis.
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same methodology as that described by White KP et al
[15] in the “London Fibromyalgia Epidemiology Study”.
In our study, this methodological approach validated by
the scientific community was used to eliminate regional
bias for the screening of patients with potential fibro-
myalgia and homogenize the fibromyalgia diagnosis in
patients screened using this method. The screening for
FM patients was conducted in 2 phases; screening of
potential patients in a representative sample of the gen-
eral population using the LFES-SQ questionnaire and
confirmation of cases of established FM by a rheumatol-
ogist, using ACR 1990 FM criteria. The medical investi-
gators involved in the study were not required to be
representative since the representation of the study
population was ensured by the sampling of the subjects
themselves. The choice of rheumatologists was preferred
for medical demographic reasons and because rheuma-
tologists are familiar with this condition. This was the
first study conducted in France combining telephone
screening and confirmation of the diagnosis based on
ACR 1990 FM criteria. Thus, accounting for the LFES-
SQ questionnaire alone, the prevalence of FM amounted
to 7.5% in the interviewed population. This prevalence
was estimated at 1.6% (95%CI:1.2%; 2.0%) when FM was
diagnosed by the rheumatologist based on ACR 1990
FM criteria. A number of FM prevalence studies have
been conducted and have demonstrated great variability
in prevalence figures between 0.5% and 57% [6], [15-20]
according to the countries, criteria and data collection
methods used. In practice, it is difficult to compare
these results, firstly, due to the lack of homogeneity in
the populations studied and, secondly, due to the
difference in the methodologies used. Nevertheless, the
prevalence of 1.6% measured in this study corroborates
the prevalence figures of 2.2% (1.3%; 3.1%) published by
Bannwarth et al [10] with another screening methodol-
ogy, without diagnosis confirmation. North American
studies [15] using the same methodology have reported
FM prevalence figures in adults not staying in healthcare
establishments of 2% to 3.3% [6,15]. The lower preva-
lence rate observed in our study could be explained by
the small number of patients accepting the visit with the
rheumatologist and by the strict application of ACR
1990 FM criteria which would explain the small number
of cases of FM confirmed by the rheumatologists in our
study. Indeed, of the 232 patients screened with the
LFES-SQ questionnaire; only 96 patients (41.4%)
accepted to attend the consultation. The diagnosis of
FM was only confirmed in 20 cases. In practice, failing a
specific biological marker for diagnosing FM, diagnosis
is based on the ACR 1990 FM classification which
recommend, in addition to chronic pain, to screen in
the clinical examination for 11 out of 18 pain points
according to a well-known topography [1]. Unlike pain
for which the characteristics are well described and
recognized, the validity of the latter criterion is debata-
ble [21-23]. Moreover, this classification does not
account for a large number of frequent pathognomonic
symptoms in this disease, such as headaches, fatigue at
the slightest exertion, tingling sensations in the body
and extreme cold intolerance at the extremities. Never-
theless, the ACR classification continues to be used rou-
tinely by rheumatologists. A survey conducted in 2003
on 1130 general practitioners and 430 rheumatologists
Table 3 Co-morbidities in CS+/CS- and FM+/FM- patient
Patients with potential or established
fibromyalgia
Patients attending consultation with
rheumatologist
CS+ CS- FM+ FM-
Number of patients 96 49 20 76
Co-morbidities (%)
Long-term fatigue [95% CI] 76.3
[67.7; 85.0]
68.9
[55.4; 82.4]
85.0
[69.4; 100.0]
74.0
[63.9; 84.0]
Cramp type digestive disorders [95% CI] 54.4
[44.2; 64.5]
52.4
[37.3; 67.5]
79.0
[60.6; 97.3]
48.0
[36.5; 59.4]
Headaches [95% CI] 53.4
[43.0; 63.8]
41.0
[25.6;56.5]
66.7
[44.9; 88.4]
50.0
[38.3; 61.7]
Anxiety 95% CI] 75.8
[67.2; 84.4]
74.4
[61.4; 87.5]
84.2
[67.8; 100.0]
73.7
[63.8; 83.6]
Depression [95% CI] 39.3
[29.2; 49.5]
40.5
[24.7;56.4]
47.4
[24.9; 69.8]
37.1
[25.8;48.5]
Rheumatoid arthritis [95% CI] 7.4
[2.1; 12.6]
19.2
[7.9; 30.4]
15.0
[0.0; 30.7]
5.3
[0.3; 10.4]
Systemic lupus erythematosus [95% CI] 1.1
[0.0; 3.2]
0.0
[0.0; 0.0]
0.0
[0.0; 0.0]
1.4
[0.0; 4.0]
CS+: patients attending consultation with rheumatologist and completing patient questionnaire; CS-: patients completing patient questionnaire without attending
consultation with rheumatologist; FM+: = confirmed diagnosis of fibromyalgia by a rheumatologist; FM-: = non-confirmed diagnosis of fibromyalgia by a
rheumatologist
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in France demonstrated that only 17.7% of general prac-
titioners knew or used the ACR criteria as opposed to
83.7% of rheumatologists [24]. In this way, indepen-
dently of the ACR criteria, new tools such as the regio-
nal pain score are developed to assist diagnosis [25,26].
This tool is based on the patient’s self-assessment of
his/her pain using a questionnaire with scores ranging
from 0 to 19. Katz et al [27], in a correlation study
between the clinical examination, regional pain score
and screening for 11 out of 18 pain points on a popula-
tion of 206 patients demonstrated the existence of a
moderate agreement between these three criteria; how-
ever, the likelihood of diagnosis of FM was higher in
patients with a high regional pain score. The author
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  p = 0.001 , 95% CI = [ 1.09 ; 1.39 ]   
Headaches 
  p = 0.211 , 95% CI = [ 0.67 ; 5.93 ]  
Odds Ratio 
Figure 3 Risk Factors associated with fibromyalgia diagnosis.
Table 4 Regional pain score
Patients with potential or established fibromyalgia Patients attending visit with rheumatologist
CS+ CS- FM+ FM-
Number of patients 96 49 20 76
Regional Pain Score
Mean ± Standard Deviation (SD) [95% CI] 9.8 ± 4.7
[8.9; 10.8]
8.5 ± 4.7
[7. 2; 10.0]
13.2 ± 4.3
[11.2;15.2]
9.0 ± 4.4
[8.0; 9.0]
CS+: patients attending consultation with rheumatologist and completing questionnaire; CS-: patients completing questionnaire but not attending consultation
with rheumatologist; FM+: = confirmed diagnosis of fibromyalgia; FM-: = non-confirmed diagnosis of fibromyalgia
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thus concludes that a regional pain score ≥ 8 associated
with a fatigue score ≥ 6 on the VAS scale could repre-
sent a valid criterion for fibromyalgia diagnosis. In our
study, a supplementary analysis of the factors associated
with FM diagnosis by the rheumatologist, independently
of ACR criteria, demonstrated a significant correlation
between the FM diagnosis and the regional pain score.
Indeed, a regional pain score greater than 10 was pre-
dictive of confirmed diagnosis by the rheumatologist
with a 75% sensitivity and a 67% specificity. Similarly,
the study demonstrated that other factors in addition to
the regional pain score were associated with an increase
in FM diagnosis. It would be worth taking these criteria
into account to increase the chances of diagnosing the
disease. This particularly applies to high stress levels,
the quality of life and the presence of co-morbidities
such as digestive disorders.
Conclusions
Using a dual method consisting of telephone screening
and clinical confirmation of the diagnosis of FM based
on ACR criteria, this study showed an overall prevalence
of FM of 1.6% (1.2%; 2.0%) in the French general popu-
lation. The analysis of the patient questionnaires
demonstrated that, independently of ACR criteria, other
criteria such as a high level of stress, low SF36 scores,
the presence of digestive disorders and a high regional
pain score could represent useful diagnostic tools in
future epidemiological studies on the prevalence of FM.
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